ProCE Banner Series

Expert Updates on the Latest Advances in the Development of Weekly Insulin Formulations

Experts on the frontlines of insulin research and patient care will provide the latest evidence on weekly insulin formulation in this live, hybrid event. Faculty will cover the latest in weekly insulin formulations – including mechanisms, efficacy, and safety as well as addressing the anticipated needs of patients and providers, once these treatments are available.

In-person attendees must register for the event on ENDO's website:

http://www.xpressreg.net/register/endo0623/landing.asp

To claim credit, please use the link below which is hosted on ENDO's website:

https://education.endocrine.org/URL/ENDO2023_Insulin

  AAPA
  | ANCC
  | AMA
Who Should Attend

This program is intended for endocrinologists and scientists who are involved and/or related to research on new insulin development and the care of patients with diabetes

All Events

Expert Updates on the Latest Advances in the Development of Weekly Insulin Formulations

Past Events

June

16

2023

6:30 PM - 8:00 PM Central Time (CT)

In-personVirtual

Faculty

ProCE Banner Faculty
Juan Pablo Frias, MD, FACE

Medical Director and Principal Investigator
National Research Institute 
Los Angeles, California

ProCE Banner Faculty
Rodolfo J. Galindo, MD, FACE

Associate Professor of Medicine
Division of Endocrinology
University of Miami Miller School of Medicine
Director
Comprehensive Diabetes Center
UM Health System
Miami, Florida

ProCE Banner Faculty
Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Topics

  • Tracking the Evolution of Insulin and the Impetus for Change
  • Overview of Weekly Insulin Formulations in Development
  • The Latest Clinical Trial Data of Weekly Insulin Formulations
  • Practical Considerations and Addressing Concerns
  • Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Target Audience
This program is intended for endocrinologists and scientists who are involved and/or related to research on new insulin development and the care of patients with diabetes.

Goal Statement
The goal of this program is to improve the knowledge and competence of endocrinologists and scientists with the latest evidence on the mechanisms, efficacy, and safety of weekly insulin formulations in development and the potential for these treatments to address challenges with current insulin therapy and achievement of glycemic goals in patients with diabetes.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify challenges with daily basal insulin that may be overcome by weekly insulin formulations in development
  • Compare the mechanism of action, efficacy, and safety of weekly insulin formulations in development with available daily basal insulins
  • Evaluate strategies to address patient and provider barriers to implementing weekly insulins into clinical practice

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit

The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Physician Associate/Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Jointly provided by Clinical Care Options, LLC and Endocrine Society.

This activity is supported by an educational grant from Lilly.